An Optimal Two-Period Multiarm Platform Design with New Experimental Arms Added During the Trial
Pub. online: 1 December 2022
Type: Cancer Research
Open Access
Open Access
1
The first two authors contributed equally.
Accepted
10 November 2022
10 November 2022
Published
1 December 2022
1 December 2022
Abstract
Platform trials are multiarm clinical studies that allow the addition of new experimental arms after the activation of the trial. Statistical issues concerning “adding new arms”, however, have not been thoroughly discussed. This work was motivated by a “two-period” pediatric osteosarcoma study, starting with two experimental arms and one control arm and later adding two more pre-planned experimental arms. The common control arm will be shared among experimental arms across the trial. In this paper, we provide a principled approach, including how to modify the critical boundaries to control the family-wise error rate as new arms are added, how to re-estimate the sample sizes and provide the optimal control-to-experimental arms allocation ratio, in terms of minimizing the total sample size to achieve a desirable marginal power level. We examined the influence of the timing of adding new arms on the design’s operating characteristics, which provides a practical guide for deciding the timing. Other various numerical evaluations have also been conducted. A method for controlling the pair-wise error rate (PWER) has also been developed. We have published an R package, PlatformDesign, on CRAN for practitioners to easily implement this platform trial approach. A detailed step-by-step tutorial is provided in Appendix A.2.
References
Atkinson, A., Donev, A. and Tobias, R. Optimum experimental designs, with SAS 34. OUP, Oxford (2007). MR2323647
EU-PEARL webinar – “Non-concurrent controls in platform trials”. https://eu-pearl.eu/workshops/non-concurrent-controls-in-platform-trials/?utm_content=196819571&utm_medium=social&utm_source=twitter&hss_channel=tw-906901452
Lee, K. M., Wason, J. and Stallard, N. To add or not to add a new treatment arm to a multiarm study: A decision-theoretic framework. Statistics in Medicine 38(18) 3305–3321 (2019). https://doi.org/10.1002/sim.8194. MR3979810
Magirr, D., Jaki, T. and Whitehead, J. A generalized Dunnett test for multi-arm multi-stage clinical studies with treatment selection. Biometrika 99(2) 494–501 (2012). https://doi.org/10.1093/biomet/ass002. MR2931269
Saville, B. R., Berry, D. A., Berry, N. S., Viele, K. and Berry, S. M. The bayesian time machine: Accounting for temporal drift in multi-arm platform trials. Clinical Trials (2022). https://doi.org/10.1177/17407745221112013.
Sridhara, R., Marchenko, O., Jiang, Q., Pazdur, R., Posch, M., Berry S., . and Lu, C. Use of nonconcurrent common control in master protocols in oncology trials: report of an American statistical association biopharmaceutical section open forum discussion. Statistics in Biopharmaceutical Research 14(3) 353–357 (2022)
Ventz, S., Cellamare, M., Parmigiani, G. and Trippa, L. Adding experimental arms to platform clinical trials: randomization procedures and interim analyses. Biostatistics 19(2) 199–215 (2018). https://doi.org/10.1093/biostatistics/kxx030. MR3799612
Wason, J., Magirr, D., Law, M. and Jaki, T. Some recommendations for multi-arm multi-stage trials. Statistical methods in medical research 25(2) 716–727 (2016). https://doi.org/10.1177/0962280212465498. MR3489662
Wason, J. M. and Jaki, T. Optimal design of multi-arm multi-stage trials. Statistics in medicine 31(30) 4269–4279 (2012). https://doi.org/10.1002/sim.5513. MR3040080
